Amgen wins patent fight with Roche

amgen

Roche's siege on Amgen anemia-drugs territory is ending with a whimper. A jury ruled that the Swiss drug maker's Mircera product infringes three Amgen patents. Short of "evaluating its legal options" in hopes of a valid appeal, there's little Roche can do to fight back now.

Roche had hoped to roll out Mircera in the U.S. this year. Roche has already introduced Mircera in several EU countries; it expects FDA approval for the drug next month. But armed with its validated patents, Amgen now plans to seek an injunction to stop the product Stateside. Mircera would compete with Epogen and Aranesp, which remain Amgen's cash-cow drugs even as debates rage over their safety.

- see Amgen's release

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

Related Articles:
Amgen flexes for Roche showdown. Report
Amgen, Roche square off. Report
Roche: Patent ruling won't stop Mircera. Report
Roche to Launch Mircera in U.K. and Germany. Report

Read more on

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.